RECURRENT BREAST CARCINOMA

This large, late-stage trial is testing whether adding a new drug called entinostat to standard hormone therapy (exemestane) works better than the hormone therapy alone. It's for people whose hormone-sensitive, advanced breast cancer has continued to grow despite prior treatment.…

This early-stage study is testing a new combination of two drugs, veliparib and carboplatin, for people with advanced HER2-negative breast cancer that has spread. The main goals are to find the safest and most effective dose and to understand the side effects. Researchers hope th…

This early-stage study is testing the safety and immune response of a new vaccine called STEMVAC in patients with advanced HER2-negative breast cancer. The vaccine aims to train the body's immune system to recognize and attack cancer cells, particularly those that are resistant t…

This study is testing if adding a new drug called copanlisib to the standard two-drug treatment (fulvestrant and abemaciclib) is more effective for advanced breast cancer that has stopped responding to hormone therapy. It will involve about 24 patients with hormone-positive, HER2…

This early-stage trial is testing whether adding an experimental drug called berzosertib to standard radiation therapy can better control breast cancer that has not responded well to chemotherapy. The main goal is to find the safest and most effective dose of the drug when given …

This study is testing whether estradiol, a form of estrogen, can help control advanced triple-negative breast cancer that has a specific biomarker called ER beta. Researchers are giving estradiol pills to 8 postmenopausal women whose cancer has spread and seeing if their tumors s…

This early-stage trial aims to find safe doses and understand side effects of several drug combinations for patients with advanced cancers that haven't responded to standard treatments. The study involves 155 participants with various advanced or metastatic cancers and some rare …

This early-stage trial is testing the safety and best doses of two different combinations of oral medications for people with recurrent endometrial, ovarian, or triple-negative breast cancer. The study combines an existing drug (olaparib) with one of two newer drugs (AZD2014 or A…

This large national trial is testing whether choosing cancer drugs based on the specific genetic changes found in a patient's tumor is more effective than standard approaches. It is for adults with advanced solid tumors, lymphoma, or multiple myeloma that have progressed after at…

This early-stage trial is testing a combination of two drugs, cyclophosphamide and veliparib, for people with advanced breast cancer that has spread. The main goal is to find the safest and most effective dose of this drug pair. Researchers will also check if certain markers in a…

This early-stage study is testing a new drug, ALRN-6924, combined with a standard chemotherapy (paclitaxel) for people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest and most effective dose of this combination an…

This study is testing whether a newer hormone therapy drug called Z-Endoxifen works better than the standard drug tamoxifen for controlling advanced breast cancer. It involves 81 postmenopausal women whose cancer has spread, is fueled by estrogen, and has stopped responding to in…

This early-stage study is testing a new hormone therapy drug called Z-Endoxifen for women with advanced breast cancer that has returned or spread. The main goals are to find the safest and most effective dose and to understand the drug's side effects. The study is for women whose…

This study aims to collect tissue samples, blood, and medical information from 300 patients with advanced breast cancer that has spread. Researchers will analyze these samples to understand why breast cancer spreads to other parts of the body and why different patients respond di…

This study aims to see if doctors can reliably measure the amount of a common chemotherapy drug (paclitaxel) in a patient's blood. The goal is to learn if tracking these levels can help find the right dose to fight cancer while reducing a severe side effect: nerve damage that cau…